Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Cytophage Technologies's cash to debt ratio for the quarter that ended in Dec. 2025 was 0.38.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Cytophage Technologiescouldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Cytophage Technologies's Cash-to-Debt or its related term are showing as below:
CPTCF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02 Med: 0.99 Max: 20.8
Current: 0.38
During the past 5 years, Cytophage Technologies's highest Cash to Debt Ratio was 20.80. The lowest was 0.02. And the median was 0.99.
CPTCF's Cash-to-Debt is not ranked
in the Biotechnology industry.
Industry Median: 7.03
vs CPTCF: 0.38
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Cytophage Technologies Cash-to-Debt Related Terms
Cytophage Technologies Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
CPTCF vs VRTX, REGN, RVMD: Cash-to-Debt Comparison
For the Biotechnology subindustry, Cytophage Technologies's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cytophage Technologies Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cytophage Technologies's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Cytophage Technologies's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cytophage Technologies (CPTCF) has a Cash-to-Debt of 0.38 as of Dec. 2025. This is 62% below median its historical median of 0.99. Over the past decade, Cytophage Technologies' Cash-to-Debt has ranged from 0.02 to 20.80.
Is Cytophage Technologies' Cash-to-Debt too high?
Cytophage Technologies' current Cash-to-Debt of 0.38 is 62% below median its 10-year median of 0.99. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 20.80. The Biotechnology industry median Cash-to-Debt is 7.03. Cytophage Technologies' value of 0.38 is 94.6% below this industry median. Overall, Cytophage Technologies has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Cytophage Technologies' Cash-to-Debt compare to VRTX and REGN?
Cytophage Technologies' Cash-to-Debt of 0.38 can be compared against companies in the Biotechnology industry. The industry median Cash-to-Debt is 7.03. Cytophage Technologies' value of 0.38 is 94.6% below this benchmark. Historically, Cytophage Technologies' own Cash-to-Debt has ranged from 0.02 to 20.80 over the past decade. While the company's 10-year median is 0.99 vs. the industry median of 7.03, Cytophage Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.03, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cytophage Technologies's current Cash-to-Debt of 0.38 is 94.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cytophage Technologies's current Cash-to-Debt is 0.38, which is 62% below median its own 10-year median of 0.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytophage Technologies stock overvalued right now?
Cytophage Technologies (CPTCF) has a current Cash-to-Debt of 0.38. The current Cash-to-Debt is 0.38, which is 62% below median its 10-year median of 0.99 and 94.6% below the Biotechnology industry median of 7.03. Cytophage Technologies' overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Cytophage Technologies (CPTCF), the current Cash-to-Debt is 0.38 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cytophage Technologies Ltd is a Canadian biotechnology company engaged in the development of bacteriophages using molecular genetics and synthetic biology techniques. The company focuses on developing bacteriophage-based solutions to address bacterial challenges affecting animal health, human health, and food security, including antibiotic-resistant bacterial strains.
18GF Score
Get the complete analysis for CPTCF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPTCF has been successfully added to your 
